MEK inhibitor. AP-1 and YAP/TAZ synergistically promotes growth-related genes [104], and, given that upstream MAPK-extracellular signal-regulated kinase pathway is frequently activated in HNSCC by EGFR or other receptor tyrosine kinases (RTKs), MEK inhibitors including trametinib can be a potential drug targeting AP-1/YAP/TAZ-driven HNSCC progression. The gene discussed is NTRK1; the disease is head and neck squamous cell carcinoma.